TRACON Pharmaceuticals Announces Reverse Stock Split
08 avr. 2024 09h10 HE
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development...
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned
03 avr. 2024 08h00 HE
|
TRACON Pharmaceuticals, Inc.
ENVASARC Trial is Fully Enrolled and Final Data are Expected in Third Quarter 2024 SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage...
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
05 mars 2024 16h02 HE
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024
28 févr. 2024 16h02 HE
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial
20 déc. 2023 08h00 HE
|
TRACON Pharmaceuticals, Inc.
Objective Response Rate by investigator review increased to 15% since interim analysis in September Full ENVASARC enrollment expected in 1Q 2024 and final data anticipated during 3Q 2024 SAN DIEGO,...
TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment
20 nov. 2023 08h00 HE
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
09 nov. 2023 16h02 HE
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023
31 oct. 2023 16h02 HE
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
18 sept. 2023 08h00 HE
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences
05 sept. 2023 16h02 HE
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...